FY2025 EPS Estimates for MaxCyte Boosted by William Blair

MaxCyte, Inc. (NASDAQ:MXCT) – Stock analysts at William Blair upped their FY2025 earnings per share estimates for MaxCyte in a report released on Thursday, November 13th. William Blair analyst M. Larew now forecasts that the company will post earnings of ($0.39) per share for the year, up from their prior estimate of ($0.46). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.27) EPS.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative net margin of 125.22% and a negative return on equity of 22.12%.

A number of other equities analysts also recently commented on the stock. BTIG Research reiterated a “neutral” rating on shares of MaxCyte in a research note on Monday, August 11th. Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Tuesday, November 11th. Finally, Stephens started coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

MaxCyte Price Performance

Shares of NASDAQ MXCT opened at $1.58 on Monday. The stock’s 50-day moving average is $1.58 and its two-hundred day moving average is $1.88. MaxCyte has a 1-year low of $1.26 and a 1-year high of $5.20. The company has a market cap of $168.44 million, a price-to-earnings ratio of -3.67 and a beta of 1.23.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MXCT. Bridgeway Capital Management LLC increased its holdings in shares of MaxCyte by 44.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 180,800 shares of the company’s stock valued at $286,000 after purchasing an additional 55,800 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in MaxCyte in the 3rd quarter valued at approximately $3,330,000. UBS Group AG raised its holdings in MaxCyte by 186.3% during the third quarter. UBS Group AG now owns 474,487 shares of the company’s stock worth $750,000 after purchasing an additional 308,769 shares during the last quarter. BNP Paribas Financial Markets grew its stake in MaxCyte by 39.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after acquiring an additional 10,263 shares during the last quarter. Finally, Willis Investment Counsel grew its position in shares of MaxCyte by 126.8% in the third quarter. Willis Investment Counsel now owns 862,758 shares of the company’s stock valued at $1,363,000 after purchasing an additional 482,287 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.